Skip to main content

Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV, Recombinant fragment - SARS-CoV-2 samples. Cited in 26 publications. Immunogen corresponding to Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein.


Images

ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073), expandable thumbnail
  • Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073), expandable thumbnail
  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073), expandable thumbnail
  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073), expandable thumbnail
  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (AB273073), expandable thumbnail

Publications

Key facts

Isotype
IgG1
Host species
Human
Storage buffer

Preservative: 0.02% Proclin 300
Constituents: PBS

Form
Liquid
Clonality
Monoclonal

Immunogen

  • Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein. The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
ELISAI-ELISA
Recombinant fragment - SARS-CoV-2
Not recommended
Tested
Recombinant full length protein - SARS-CoV
Tested
Not recommended
Recombinant full length protein - SARS-CoV-2
Tested
Not recommended
SARS-CoV
Predicted
Predicted
SARS-CoV-2
Predicted
Predicted

Tested
Tested

Species
Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV
Dilution info
-
Notes

-

Predicted
Predicted

Species
SARS-CoV, SARS-CoV-2
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Recombinant fragment - SARS-CoV-2
Dilution info
-
Notes

-

Tested
Tested

Species
Recombinant fragment - SARS-CoV-2
Dilution info
-
Notes

-

Predicted
Predicted

Species
SARS-CoV, SARS-CoV-2
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV
Dilution info
-
Notes

-

Associated Products

Select an associated product type

1 product for Alternative Version

Target data

Function

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed:32142651, PubMed:32155444, PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed:34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed:32075877, PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294, PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed:32817270). Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.

Alternative names

Recommended products

Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, I-ELISA and reacts with Recombinant full length protein - SARS-CoV-2, Recombinant full length protein - SARS-CoV, Recombinant fragment - SARS-CoV-2 samples. Cited in 26 publications. Immunogen corresponding to Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein.

Key facts

Isotype
IgG1
Form
Liquid
Clonality
Monoclonal
Immunogen
  • Cell preparation containing SARS-CoV-2 Spike Glycoprotein S1 protein. The exact immunogen used to generate this antibody is proprietary information.
Clone number
CR3022
Purification technique
Affinity purification Protein A
Epitope
This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).
Light chain type
kappa
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes (16796401).

CR3022 has been shown to bind with a high affinity to SARS-CoV2 (32416259, 32413276). Structural modelling has confirmed that CR3022 targets a conserved epitope between SARS-CoV and SARS-CoV2 in the RBD domain (32245784, 32065055). Precisely, this antibody binds to the 'open' conformation of the spike protein to the amino acids 318-510 in the S1 domain of the SARS-CoV as well as SARS-CoV-2 strains (32245784, Joyce et al. 2020). The antibody is also able to bind the P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope of clone CR3022 does not overlap with the ACE2 binding site of SARS-COV2 (32065055). Therefore whilst CR3022 can neutralise SARS-COV in in a concerted action with clone CR3014, CR3022 is not believed to independently neutralise SARS-COV2, based on in vitro studies (32226289, 32065055, 32383254, 32416259).

Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody (ab273073) is a Human IgG1 Recombinant version of CR3022 for research use only. CR3022 is also available as a chimeric rabbit antibody (Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Rabbit IgG (Chimeric) ab273074).

Applications overview

Tick: Tested and Guaranteed to work X: Will not work —: No data

ab273073 was developed to have a human IgG1 isotype.
Other isotypes of clone CR3022 available:
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] ab278112 – human IgA
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] ab278111 – human IgM
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Rabbit IgG (Chimeric) ab273074 – rabbit IgG
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Rat IgG2a (Chimeric) ab273886 – rat IgG2a

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

The SARS-CoV-2 Spike Glycoprotein S1 also known as the G10 spike or glycoprotein spike plays an important role in allowing the virus to attach and enter host cells. This protein with a mass of approximately 180 kDa is located on the surface of the virus and forms the outer spikes observed in coronaviruses. Expression of the spike glycoprotein is in virus-infected cells where it facilitates the interaction with host cell receptors. The S1 subunit includes a receptor-binding domain that specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptors initiating the infection process.

Biological function summary

The spike glycoprotein S1 mediates the fusion of the viral and cellular membranes which is necessary for viral entry. It forms part of a larger trimeric complex comprising S1 and S2 subunits. This complex undergoes conformational changes that drive the membrane fusion process. The glycoprotein contains multiple glycosylation sites which help shield the virus from the host immune response. The proper function and presentation of this glycoprotein are critical for efficient viral spread and infection establishment.

Pathways

The spike glycoprotein S1 is integral to the viral infection pathway and host immune evasion. It interacts with the renin-angiotensin system by binding to the ACE2 receptor disrupting normal receptor activity. This interaction not only facilitates viral entry but also impacts the homeostatic functions typically mediated by ACE2 which include blood pressure regulation. Additionally the spike protein is involved in downstream activation of immune signaling pathways including those related to inflammation and cytokine production which may involve proteins such as IL-6.

Associated diseases and disorders

Infection with the spike glycoprotein S1 is directly related to COVID-19. The binding to ACE2 receptors is linked to the pathology of the disease contributing to respiratory symptoms and in severe cases acute respiratory distress syndrome (ARDS). Through the IL-6 signaling pathway the spike protein is indirectly connected to cytokine release syndrome often observed in severe COVID-19 cases. This connection highlights the importance of targeting this glycoprotein for potential therapeutic interventions and diagnostics such as ELISA SARS-CoV-2 tests and the development of anti-spike antibodies available on platforms like antispark.com for research and clinical purposes.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

5 product images

  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073), expandable thumbnail

    ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)

    ELISA using ab273073 and mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. RBD WT – wild-type receptor binding domain.

  • Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073), expandable thumbnail

    Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)

    Indirect ELISA showing primary antibody ab273073 (CR3022, human chimeric) binding to the antigens Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) and Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) ab273068 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active)). Plates were coated with 100ng/well Recombinant Human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Fc Chimera) ab272105 or Recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active) ab273068 and binding of ab273073 assessed in serial dilution from 200ng/ml primary antibody in duplicate. Binding was detected using Goat Anti-Human IgG Fc (HRP) preadsorbed ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.

  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073), expandable thumbnail

    ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)

    ELISA using ab273073 with UK (B.1.1.7) and South African (B.1.351 (501Y.V2)) mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 μg/ml. ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (ab01680) exhibited exceptional binding to all mutant spike proteins. WT – wild type.

  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073), expandable thumbnail

    ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)

    Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin.

    ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) at concentrations of 5 μg/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using ab273073.

    For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.

  • ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073), expandable thumbnail

    ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)

    Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells.

    ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells at concentrations of 5 μg/ml. A 3-fold serial dilution from 125 ng/ml was performed using ab273073.

    For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com